No Data
No Data
Shenzhen Hepalink Shareholders Approve Key Resolutions
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Hyperlink (002399.SZ/9989.HK): 2024Q1 net profit to mother increased 133% year-on-year, steady operation continued to improve
In an environment where the external market is still full of uncertainty, the disclosure of the 2023 report and 2024 quarterly report related to A-shares has come to an end. Looking back at 2023, companies related to the heparin industry faced quite a few challenges under stress tests in the face of declining pig cycles. However, at the beginning of 2024, along with the gradual stabilization of the bottom of pig prices, some leading companies have improved significantly and shown strong resilience. Among them, Hapley, a leading company in the heparin industry, also handed over a report in the first quarter of 2024 with a 133% year-on-year increase in net profit, outperforming the industry's performance during the same period. Hypri publishes quarterly report
Closing up 42% at the end of the session, is it still too early to say that Junshengtai Pharmaceutical-B (02511) broke out of the trough?
With high investment in R&D, capital consumption will also increase. Whether the current cash can support the commercialization of Junshengtai's core products is still unknown.
Why Investors Shouldn't Be Surprised By Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 2.8x Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) is a stock worth checking out, seeing as almost half of all the Pharmac
Changes in Hong Kong stocks | Hapley (09989) A shares rose or stopped, and H shares once rose more than 11%, net profit to mother increased 1.33 times year-on-year in the first quarter
Hypry (09989) A-shares rose to a halt. As of press release, H shares rose 8.59% to HK$3.54, with a turnover of HK$124.367 million.
No Data